Shanghai Regenelead Therapies Co., Ltd.

Brief Summary: This study is an open, prospective, exploratory clinical trial designed to evaluate the safety,ability, immunogenicity, and preliminary efficacy of a personalized neoantigen mRNA vaccine in combination with adebelimab as adjuvant treatment for patients with non-small cell lung cancer (NSCLC).
The primary objectives of this study are to answer the following key questions:
1. The incidence of dose-limiting toxicities (DLTs) during the designated observation period.
2. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
3. The determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD).

主要研究目的：评价在严重下肢缺血患者中单次肌肉注射RGL-2102的安全性和耐受性。 次要研究目的：评价在严重下肢缺血患者中单次肌肉注射RGL-2102的药代动力学（PK）特征及免疫原性。 探索性研究目的：探索在严重下肢缺血患者中单次肌肉注射RGL-2102的初步有效性。

This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected pancreatic adenocarcinoma.